These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17898810)

  • 1. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
    Pan M; Santamaria M; Wollman DB
    Nat Clin Pract Oncol; 2007 Oct; 4(10):603-7. PubMed ID: 17898810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
    Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
    Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
    Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
    Mairovitz A; Staub E; Le Floch H; Rivière F; Bonnichon A; Margery J; Vaylet F
    Rev Pneumol Clin; 2009 Oct; 65(5):318-21. PubMed ID: 19878809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
    Bai H; Han B
    Am J Clin Oncol; 2013 Apr; 36(2):110-5. PubMed ID: 22391431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
    Tsao MS; Sakurada A; Cutz JC; Zhu CQ; Kamel-Reid S; Squire J; Lorimer I; Zhang T; Liu N; Daneshmand M; Marrano P; da Cunha Santos G; Lagarde A; Richardson F; Seymour L; Whitehead M; Ding K; Pater J; Shepherd FA
    N Engl J Med; 2005 Jul; 353(2):133-44. PubMed ID: 16014883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
    Jamal-Hanjani M; Spicer J
    Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
    Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
    Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
    Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
    Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
    Chang JW; Chou CL; Huang SF; Wang HM; Hsieh JJ; Hsu T; Cheung YC
    Lung Cancer; 2007 Dec; 58(3):414-7. PubMed ID: 17618013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
    Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
    Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain metastasis responding to gefitinib alone.
    Poon AN; Ho SS; Yeo W; Mok TS
    Oncology; 2004; 67(2):174-8. PubMed ID: 15539923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    Pao W; Miller VA
    J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.